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Abstract 31 
Eldecalcitol (ELD), an active form of vitamin D analog approved for the treatment of osteoporosis in Japan, 32 
increases lumbar spine bone mineral density (BMD), suppresses bone turnover markers, and reduces fracture 33 
risk in patients with osteoporosis. We have previously reported that treatment with ELD for 6 months 34 
improved the mechanical properties of the lumbar spine in ovariectomized (OVX) cynomolgus monkeys. ELD 35 
treatment increased lumbar BMD, suppressed bone turnover markers, and reduced histomorphometric 36 
parameters of both bone formation and resorption in vertebral trabecular bone. In this study, we elucidated the 37 
effects of ELD on bone quality (namely, mineralization, microarchitecture, microdamage, and bone collagen 38 
crosslinks) in OVX cynomolgus monkeys in comparison with OVX-vehicle control monkeys. Density 39 
fractionation of bone powder prepared from lumbar vertebrae revealed that ELD treatment shifted the 40 
distribution profile of bone mineralization to a higher density, and backscattered electron microscopic imaging 41 
showed improved trabecular bone connectivity in the ELD-treated groups. Higher doses of ELD more 42 
significantly reduced the amount of microdamage compared to OVX-vehicle controls. The fractionated bone 43 
powder samples were divided according to their density, and analyzed for collagen crosslinks. Enzymatic 44 
crosslinks were higher in both the high-density (≥2.0 mg/mL) and low-density (<2.0 mg/mL) fractions from 45 
the ELD-treated groups than in the corresponding fractions in the OVX-vehicle control groups. On the other 46 
hand, non-enzymatic crosslinks were lower in both the high- and low-density fractions. These observations 47 
indicated that ELD treatment stimulated the enzymatic reaction of collagen crosslinks and bone mineralization, 48 
but prevented non-enzymatic reaction of collagen crosslinks and accumulation of bone microdamage. Bone 49 
anti-resorptive agents such as bisphosphonates slow down bone remodeling so that bone mineralization, bone 50 
microdamage, and non-enzymatic collagen crosslinks all increase. Bone anabolic agents such as parathyroid 51 
hormone decrease bone mineralization and bone microdamage by stimulating bone remodeling. ELD did not 52 
fit into either category. Histological analysis indicated that the ELD treatment strongly suppressed bone 53 
resorption by reducing the number of osteoclasts, while also stimulating focal bone formation without prior 54 
4 / 27 
bone resorption (bone minimodeling). These bidirectional activities of ELD may account for its unique effects 55 
on bone quality. 56 
Keywords: vitamin D, bone quality, bone mineralization, bone microdamage, bone microarchitecture, 57 
collagen crosslinks 58 
59 
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1.  Introduction 60 
Bone mineral density (BMD) and bone quality are two major components of bone strength. Bone quality 61 
consists of bone geometry, bone microarchitecture, bone microdamage, bone mineralization, and bone material 62 
properties. These determinants of bone quality are regulated by bone turnover and the degree of oxidative 63 
stress [1][2][3]. Eldecalcitol [1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3; ELD], an analog of 64 
calcitriol [1α,25-dihydroxyvitamin D3; 1,25(OH)2D3], has been demonstrated to increase bone mass, to 65 
suppress bone turnover markers, and to enhance bone strength in rodents [4][5] and in non-human primates 66 
[6]. ELD suppresses RANKL expression in osteoblasts [7], suppresses differentiation of preosteoclasts to 67 
mature osteoclasts [8], stimulates cell-migration of osteoclast precursor monocytes [9], and therefore, reduces 68 
the number of mature osteoclasts on the bone surface. A 3-year randomized, double-blind, active-comparator, 69 
clinical trial of ELD in postmenopausal women with osteoporosis demonstrated that ELD significantly 70 
decreased the incidence of vertebral fractures and wrist fractures, increased both lumbar spine and hip BMD, 71 
and suppressed bone turnover markers in comparison to alfacalcidol (1α-hydroxyvitamin D3) [10]. 72 
Deterioration of bone architecture in the hip was reduced by ELD treatment [11]. A post-hoc analysis revealed 73 
that, compared with placebo, ELD reduced incidence of vertebral fractures by approximately 50% in 74 
osteoporotic patients with prevalent fractures [12]. This series of results raises an important question. 75 
Treatment with ELD increases lumbar spine BMD by only 3% per year and reduces bone turnover markers by 76 
approximately 30% per year compared with the pretreatment level. On the other hand, treatment with most 77 
bisphosphonates increases lumbar spine BMD by more than 5% per year and reduces bone turnover markers 78 
by 50%–60% per year. Despite its more restrained effects on BMD and bone turnover markers, the anti-79 
fracture activity of ELD is comparable to that of bisphosphonates [13]. These differences suggest that in 80 
addition to the effects of ELD on BMD and bone turnover markers, the anti-fracture activity of ELD treatment 81 
may be attributable to improved bone quality. 82 
We have previously shown that treatment with 0.1 µg/kg/day and 0.3 µg/kg/day of ELD increases lumbar 83 
spine and hip BMD, suppresses bone turnover markers, and eventually increases bone mechanical properties of 84 
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lumbar vertebrae in ovariectomized (OVX) cynomolgus monkeys [6]. Unlike rodent models, ovariectomized 85 
non-human primates have a skeletal anatomy and bone material properties in terms of collagen crosslink 86 
formation similar to those of postmenopausal women, with intracortical bone remodeling and increased bone 87 
turnover and bone loss associated with estrogen deficiency [14][15].  88 
Regarding bone material properties, collagen crosslinking is an independent determinant of bone 89 
strength [3][16]. Bone collagen crosslinks can be divided into immature and mature enzymatic crosslinks and 90 
glycation- or oxidation-induced non-enzymatic senescent crosslinks (advanced glycation end products, AGEs). 91 
Enzymatic crosslink formation has positive effects on the mechanical properties of bone, conferring flexibility 92 
without brittleness [17][18][19][20][21]. In contrast, AGE crosslinks result in brittle collagen fibers, thereby 93 
leading to microdamage and bone fragility [17][22][23]. AGE crosslinks are formed by oxidation or glycation 94 
reactions in a time-dependent manner, and are regulated by tissue turnover rate [22][24], the degree of 95 
oxidative stress [25][26], or glycation level [17][23]. Pentosidine is a well-established intermolecular 96 
crosslinking AGE and is used as a surrogate marker of total AGE formation [17][26][27][28][29][30]. 97 
In this study, in order to evaluate the effect of ELD on bone material and structural properties, we 98 
analyzed bone mineralization, bone microarchitecture, bone microdamage, immature and mature enzymatic 99 
collagen crosslinks, and AGEs in the bone samples collected for the OVX cynomolgus monkey study 100 
previously reported [6]. 101 
2.  Materials and Methods 102 
2.1  Animals and experimental design 103 
All animal procedures were as previously reported [6]. Briefly, 40 female cynomolgus monkeys, at least 104 
9 years of age, were housed in pairs and fed twice daily with food supplements and/or fresh fruit, and had free 105 
access to water. The animal room environment was controlled, with settings targeted at a temperature of 106 
22±3°C, humidity of 50±20%, photoperiod of 12 h light and 12 h dark, and 12 air changes per hour. Two 107 
separate experiments were conducted, one experiment using a dose of 0.1 µg/kg ELD and a corresponding 108 
OVX-vehicle control group and the other experiment using 0.3 µg/kg ELD and a corresponding OVX-vehicle 109 
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control group. Medium chain triglyceride was used for the vehicle solution. For each experiment, 20 animals 110 
were randomly assigned to either the OVX-vehicle control group or the ELD group (n = 10/group). The groups 111 
were balanced to ensure that age, body weights, whole body bone mineral content (BMC), and lumbar spine 112 
BMD were equivalent across groups within each experiment. 113 
Daily treatment started the day following ovariectomy, with either vehicle alone (OVX-Veh1 or OVX-114 
Veh2) or ELD (at 0.1 µg/kg in the first experiment or 0.3 µg/kg in the second experiment), and continued for 115 
6 months. Animals were euthanized under anesthesia by exsanguination, and bone samples were excised. The 116 
study was approved by the Charles River Montreal Animal Care Committee and was performed in a facility 117 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. 118 
2.2  Density fractionation 119 
Density fractionation was carried out as previously reported [31][32][33]. Briefly, the third lumbar vertebrae 120 
(L3) were crushed and washed in 0.2M Tris-HCl buffer (pH7.4) to remove bone marrow, lyophilized, and then 121 
defatted in 2:1 (v:v) chloroform:methanol solution. The bone pieces were then pulverized in a percussion mill 122 
cooled in liquid nitrogen (Spex Freezer Mill; Spex Sampleprep, Metuchen, NJ, USA) and then sieved in a 123 
sonic sifter to separate bone particles less than 20 µm in size. The bone powder was then chemically 124 
―fractionated‖ (into seven fractions from < 1.8 g/mL to > 2.1 g/mL) in a bromoform–toluene mixtures by a 125 
method of stepwise centrifugation [33]. Approximately 200 mg of the sieved bone was added to a polyallomer 126 
centrifuge tube containing 35 mL of a 1.95 g/mL density solution (calibrated with sink floats) for cancellous 127 
bone. The tubes were sonicated to achieve a homogeneous suspension of the powder, which was then 128 
centrifuged at 10,000 rpm for 30 min in a Beckman L5-55 ultracentrifuge using an SW20 rotor. The density of 129 
the supernatant was adjusted to 1.9 g/mL via the addition of toluene, and the modified solution was re-130 
centrifuged. In a similar way, each precipitate obtained from a solution of progressively decreasing density (in 131 
0.05 g/mL steps) was collected. For the range of mineral densities greater than 1.95 g/mL, the precipitates 132 
obtained from an initial 2.0 g/mL density solution was re-suspended in a solution of density 2.1 g/mL. 133 
Similarly, successive centrifugation of the precipitate at progressively higher densities (0.05 g/mL steps) 134 
determined the higher density fractions.  135 
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Removal of organic solvent from the series of density fractions was achieved by a ―rinse‖ centrifugation in 136 
100% ethyl alcohol. The samples were then dried in a desiccator at room temperature. The contribution of each 137 
fraction, relative to the original weight of unfractionated bone, was calculated to determine a mineralization 138 
profile for each group. 139 
2.3  Bone microdamage assessment 140 
The fourth lumbar vertebrae (L4) were processed for microdamage assessment by bulk staining in basic 141 
fuchsin. Using 1% basic fuchsin dissolved in increasing concentrations of ethanol, specimens were stained 142 
according to the following schedule: 4 h in 80%, 4 h in 80%, 4 h in 95%, overnight in 95%, 4 h in 100%, and 143 
4 h in 100%. At each step, the solution was replaced with fresh solution after 2 h. Bones were placed under 144 
vacuum (20 in Hg) for all stages during the day and left on the bench top overnight. Following staining, bones 145 
were washed twice in 100% ethanol (5 min each), and placed in 100% methylmethacrylate (MMA; Sigma-146 
Aldrich) under vacuum for 4 h. Specimens were then transferred to a solution of MMA + 3% dibutyl phthalate 147 
(DBP; Sigma-Aldrich) for 3–7 days under vacuum and then embedded using MMA + DBP + 0.25% catalyst 148 
(Perkadox 163; Akzo Nobel Chemicals, Pasadena, USA). Mid-sagittal sections 80–100 µm thick were cut 149 
using a diamond wire saw (Histosaw; Delaware Diamond Knives, Inc., DE, USA). 150 
Histological measurements were made using a microscope interfaced with Bioquant analysis software 151 
(Bioquant OSTEO 7.20.10; Bioquant Image Analysis Co., TN, USA). Measurements were carried out on two 152 
sections per animal to increase the probability of finding cracks. A region of interest approximately 5 × 5 mm, 153 
located 1 mm below the cranial plateau, was used for sampling, and linear microcracks were identified as 154 
previously described [34]. Measurements included crack length (Cr.Le; 200× magnification) (μm) and crack 155 
number (Cr.N; 100× magnification), with calculations of crack density (Cr.Dn = Cr.N/bone area) (/mm
2
) and 156 
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2.4  Bone microarchitecture assessment by backscattered electron microscopy 159 
The resin-embedded L4 vertebrae blocks prepared for microdamage analysis were cut with a saw, polished to a 160 
1 µm diamond finish, then carbon coated. We used a scanning electron microscope (XL30; Philips/FEI, 161 
Oregon, USA) fitted with a backscattered electron detector (Philips/FEI). The signal was calibrated using C 162 
(Z = 6) and A1 (Z = 13), then the settings were changed to increase the contrast of the bone signal (Z = approx. 163 
10). During the acquisition session, we controlled the drift of the signal using SiO2 as a standard (only for 164 
slight adjustments). The accelerating voltage was 20 kV. Digital images were collected at 80× magnification; 165 
adjacent images were obtained on each block. 166 
Image analysis was performed with a Quantimet 500 IW using Qwin Pro (Leica Microsystems, 167 
Cambridge, UK). The images were converted to binary images using a constant threshold of 85. The binary 168 
images were then skeletonized and pruned to quantify the number of nodes (/mm
2
), number of termini (/mm
2
), 169 





), and terminus-to-terminus struts (mm/mm
2
), and the total strut length (mm/mm
2
). 171 
Of these parameters, the increase in the number of nodes, node-to-node struts, and node-to-terminus struts can 172 
be related to the connectedness of the structure. Struts reaching the borders of the images were not considered 173 
except for the total strut length.  174 
2.5  Collagen crosslink analysis 175 
The procedure to analyze collagen crosslinks in bone after the density fractionation was as reported 176 
previously [27][29][30]. Briefly, density-fractionated bone powders of the third lumbar vertebrae were 177 
subjected to the collagen crosslink analysis. Fractionated bone powders were pooled into two fractions: low-178 
density fraction (< 2.0 mg/mL) and high-density fraction (≥ 2.0 mg/mL). We defined the boundary line 179 
between the low- and high-density fractions at 2.0 mg/mL based on the report by Sodek et al.[31]. By 180 
separating bone at the 2.0 mg/mL boundary line, we obtained sufficient bone from both low- and high-density 181 
fractions for triplicate analyses of two different density fractions, suitable for estimating the collagen 182 
maturation process [29][30]. Toluene and bromoform used for the bone density fractionation do not affect the 183 
biochemical nature of bone collagen and its crosslinks [30]. 184 
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Each sample of bone powder was demineralized twice with 0.5 M EDTA in 50 mM Tris buffer (pH 7.4) 185 
for 96 h at 4°C. The demineralized bone residues were then suspended in 0.15 M potassium phosphate buffer 186 
(pH 7.6) and reduced at 37°C with NaBH4. The reduced specimens were hydrolyzed in 6 N HCl at 110°C for 187 
24 h. Hydrolysates were analyzed for the content of crosslinks and hydroxyproline on a Shimadzu LC9 HPLC 188 
fitted with a cation exchange column (0.9 × 10 cm, Aa pack-Na; JASCO, Ltd., Tokyo, Japan) linked to an 189 
inline fluorescence flow monitor (RF10AXL; Shimadzu, Shizuoka, Japan). It was assumed that collagen 190 
weighed 7.5 times the measured hydroxyproline weight with a molecular weight of 300,000. The resulting data 191 
were used to calculate the cross-link values as mol/mol of collagen. Reducible immature divalent crosslinks 192 
(dehydrodihydroxylysinonorleucine, deH-DHLNL; dehydrohydroxylysinonorleucine, deH-HLNL; and 193 
dehydrolysinonorleucine, deH-LNL) were identified and quantified according to their respective reduced 194 
forms (dihydroxylysinonorleucine, DHLNL; hydroxylysinonorleucine, HLNL; and lysinonorleucine, LNL). 195 
The mature crosslinks and common amino acids such as hydroxyproline were detectable with post-column 196 
derivatization using o-phthalaldehyde, whereas the mature trivalent pyridinium crosslinks (pyridinoline, Pyr; 197 
and deoxypyridinoline, Dpyr) and the non-enzymatic crosslink pentosidine (Pen) were detected by natural 198 
fluorescence. The HPLC system we established enabled us to determine enzymatic and non-enzymatic 199 
crosslink contents within a linear range of 0.2 to 600 pmol in bone specimens. The total content of AGEs as 200 
well as pentosidine content was determined by the method of Tang et al.[35]. Briefly, AGE content was 201 
determined by using a fluorescence reader at 370 nm excitation and 440 nm emission (JASCO FP6200, 202 
JASCO) and normalized to a quinine sulfate standard. Data were expressed as mean ± standard deviation (SD).  203 
2.6 Bone histology 204 
Each animal had been subcutaneously injected with 8 mg/kg of calcein 15 days and 5 days prior to termination. 205 
L2 vertebrae were collected for bone histology. All bone samples were fixed in 10% neutral-buffered formalin 206 
for 3 days and transferred to 70% ethanol. Bones were then trimmed, dehydrated, and embedded in methyl 207 
methacrylate. Sagittal histological sections of L2 vertebrae were observed under a light microscope after 208 
toluidine blue staining for evaluating bone histology, or under a fluorescence microscope for visualizing 209 
calcein labeling (Nikon Eclipse E800; Nikon, Tokyo, Japan). 210 
11 / 27 
2.7 Statistical analysis 211 
2.7.1 Density fractionation;  212 
Data were analyzed as previously described [36]. The way to estimate if two distributions differ is to calculate 213 
the logit function of each distribution. For these experiments, the logit number of each sample is: ln(proportion 214 
of ≥ 2.00 mg/mL fraction) ‒ ln(proportion of < 2.00 mg/mL fraction). The statistical analyses were performed 215 
using SPSS software (IBM, Armonk, NY, USA). 216 
2.7.2 Bone microdamage assessment 217 
Data from each experiment was evaluated separately using the SAS software package (SAS Institute, Inc., 218 
Cary, NC, USA). Group variance was evaluated using the Shapiro-Wilks test. If the assumption of normality 219 
was met (p  ≥ 0.05), a parametric two-tailed t-test was performed to determine differences between the control 220 
and treated groups. If the assumption of normality was not met, for either/both groups (p < 0.05), the non-221 
parametric Wilcoxon-Mann-Whitney test (two-tailed) was used to compare the control and treated groups. 222 
Spearman’s rank correlation coefficient method was used to analyze the correlation between the contents of 223 
Pen and total fluorescent AGEs in bone. For all comparisons, both parametric and non-parametric tests are 224 
reported, with p < 0.05 considered statistically significant. 225 
2.7.3 Bone microarchitecture assessment 226 
The statistical analyses were performed using SPSS software (IBM, Armonk, NY, USA). Independent 227 
Student’s t-tests were done between the ELD treatment group and corresponding vehicle control group for 228 
each experiment. P-values less than 0.05 were considered significant. 229 
2.7.4 Collagen crosslink analysis 230 
Analysis of variance was performed using the SAS software package (SAS Institute). The significance of 231 
differences (in comparison with the OVX-vehicle control group) was determined using the Tukey-Kramer test. 232 
P-values less than 0.05 were considered statistically significant. 233 
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3.  Results 234 
3.1  Bone mineralization assessment by density fractionation 235 
Treatment with 0.1 µg/kg or 0.3 µg/kg of ELD shifted the distribution profile of bone mineralization to a 236 
higher density compared with the corresponding vehicle controls (Fig. 1A, 1B). The average logit number of 237 
the ELD 0.3 µg/kg group and the OVX-Veh2 control group were -0.394 and 1.009, respectively (Fig. 1D). The 238 
shift in the value of the logit function between two groups was significant (p = 0.0002). The average logit 239 
number of the ELD 0.1 µg/kg group and the OVX-Veh1 were 1.439 and 1.842, respectively (Fig. 1C). But 240 
there was no significant difference between the value of the logit function of the ELD 0.1 µg/kg group and the 241 
OVX-Veh1 control group (p = 0.270). 242 
3.2  Bone microdamage 243 
There were no significant differences between the ELD 0.1 µg/kg group and OVX-Veh1 control group for any 244 
of the microdamage variables measured (Table 1). The ELD 0.3 µg/kg group had half as many cracks as the 245 
OVX-vehicle group (p = 0.052). When normalized for bone area, the ELD 0.3 µg/kg group had significantly 246 
lower crack density (p = 0.027) and crack surface density (p = 0.049) as compared to the OVX-Veh2 control 247 
group. There was no significant difference between groups for crack length (Table 1). 248 
3.3  Bone microarchitecture 249 
The results of the strut analysis of the trabecular bone from the L4 vertebrae are shown in Table 2. These data 250 
were derived from the backscattered electron microscopic images (Fig. 2). The results are consistent with 251 
increased trabecular connectivity as demonstrated by a higher number of nodes and node-to-node strut lengths 252 
as well as a lower number of termini and terminus-to-terminus strut lengths with both 0.1 µg/kg and 0.3 µg/kg 253 
of ELD. 254 
3.4  Enzymatic and non-enzymatic collagen crosslinks 255 
The total enzymatic crosslink content (the sum of DHLNL, HLNL, LNL, Pyr, and Dpyr) in both low- and 256 
high-density fractions from bones of the ELD-treated (0.1 and 0.3 µg/kg) groups were significantly higher than 257 
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those of the corresponding OVX-vehicle control groups (Fig. 3A, 3C, and Table 3). Notably, immature 258 
reduced forms of enzymatic crosslinks (DHLNL, HLNL, and LNL) significantly and markedly increased with 259 
ELD treatment, whereas increases in mature non-reducible forms of enzymatic crosslinks (Pyr and Dpyr) by 260 
the ELD treatment were significant but moderate (Table 3).  261 
We calculated the biochemical collagen maturation index, defined as the ratio of total mature enzymatic 262 
crosslinks (Pyr+Dpyr) to total immature crosslinks (DHLNL+HLNL+LNL) [29][30][35] (Table 3). The 263 
maturation index showed a significant reduction in both low- and high-density fractions of bone from the 264 
ELD-treated groups compared with those from the corresponding OVX-vehicle control groups. Conversely, 265 
contents of Pen, the non-enzymatic AGE type of crosslink, were significantly lower in both low- and high-266 
density fractions from bones of the ELD-treated groups than in those of the corresponding OVX-vehicle 267 
control groups (Fig. 3B, 3D, and Table 3). 268 
Regarding total fluorescent AGEs, results similar to those of Pen are evident (Table 3). Pen is just a 269 
component of various AGEs, and because the content of Pen in bone correlates positively with the total 270 
amount of fluorescent AGEs, the measurement of Pen can be used as a surrogate marker of total AGE 271 
formation [37]. In this study, we also confirmed that there was a significant and positive correlation between 272 
the content of Pen and the total fluorescent AGEs in bone (R
2
 = 0.339, p < 0.0001) (data not shown). The 273 
contents of the senescent crosslinking Pen and total contents of AGEs were significantly higher in the high-274 
density fractions than in the low-density fractions in both the OVX-vehicle and ELD-treated groups (all 275 
p < 0.05, Table 3). 276 
3.5  Bone histology 277 
Trabecular bone sections of the ELD-treated cynomolgus monkeys demonstrated many ―bud-like‖ bone 278 
formation patterns (Fig. 4A). Convex, bud-like focal deposits of bone matrix were observed on the smooth line 279 
forming the boundary to the underlying bone matrix. Bone specimens from the ELD-treated OVX monkeys 280 
revealed various bone buds labeled with continuous lines of calcein (Fig. 4B). No monkeys in the vehicle-281 
treated control group in this study had such focal bone formation. These findings in the ELD-treated monkeys 282 
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are similar to the histological features of bone minimodeling found in our previous studies using ELD-283 
administered OVX rats [8][38]. 284 
4.  Discussion 285 
We have previously reported that ELD treatment for 6 months increased lumbar spine BMD, suppressed 286 
ovariectomy-induced increases in bone turnover markers, and improved biomechanical parameters of lumbar 287 
vertebrae in OVX cynomolgus monkeys [6]. Histomorphometrical analysis of bone revealed that both bone 288 
formation and bone resorption parameters in the trabecular bones of the lumbar vertebrae were suppressed by 289 
the ELD treatment. Therefore, we concluded that, in a bone-remodeling animal model, ELD increases BMD 290 
and improves bone biomechanical properties, at least, in part, by normalizing bone turnover. In that study, 291 
treatment with ELD at doses of 0.1 µg/kg and 0.3 µg/kg for 6 months increased lumbar spine (L1–L4) BMD 292 
by 7.7% and 10.8%, respectively, compared to the corresponding OVX-vehicle controls, and increased the 293 
peak load of intact L3 vertebra in a compression test by 26.4% and 84.2%, respectively. Those observations 294 
indicated that the ELD treatment improved bone mechanical properties more than could be explained by the 295 
increase in BMD. Comparing those results with the results from studies of other anti-osteoporotic agents in the 296 
OVX monkey model, even though bisphosphonates such as clodronate, ibandronate, and minodronate 297 
increased lumbar spine BMD by more than 10%–30%, they improved peak load in the compression test by 298 
only approximately 30% [39][40][41]. 299 
Bone density fractionation of the vertebral body in the current study revealed that the ELD treatment 300 
slightly shifted bone mineralization to a higher density. As previously reported, osteoid surface (OS/BS), 301 
osteoid thickness (O.Th), and activation frequency (Ac.f) were reduced in the lumbar vertebral trabecular bone 302 
of the ELD-treated groups compared with those of the OVX control groups [6]. However, ELD treatment did 303 
not overly affect osteoid maturation time (Omt). These bone histomorphometrical data indicate that ELD does 304 
not accelerate osteoid mineralization and facilitates secondary mineralization in the vertebral bone by slowing 305 
down bone remodeling. Trabecular connectivity of the lumbar vertebra was increased by the ELD treatment. 306 
Trabecular bones from ELD-treated groups had higher node-to-node strut length and lower terminus-to-307 
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terminus strut length than did trabecular bones from the OVX control groups. In general, if BMD is equal, 308 
higher connectivity means a stronger bone. Therefore, improvement of trabecular connectivity in lumbar 309 
vertebrae may partly account for the improvement of biomechanical properties in compression. 310 
There are several reports on the effects that various agents for the treatment of osteoporosis have on the 311 
material properties of bone. Long-term treatment with bisphosphonates has been shown to increase the 312 
accumulation of non-enzymatic AGE crosslinks and increase bone microdamage in canine trabecular bone [22] 313 
[42][43]. Damaged bone tissue is slowly resorbed by osteoclasts and replaced by new bone tissue during the 314 
bone remodeling process. When bone remodeling is suppressed with agents such as bisphosphonates, the 315 
microdamage in the old bone tissues accumulates due to both a reduction in the removal of damaged bone 316 
tissue and an increase in its formation. There is no concrete evidence that the levels of microdamage 317 
accumulation that occur in vivo weaken overall bone mechanical properties. We did not find increases in any 318 
parameters of bone microdamage in the bone specimens from the ELD-treated groups (Table 2) compared with 319 
those from OVX control groups. Rather, 0.3 µg/kg of ELD treatment reduced crack density and crack surface 320 
density of lumbar vertebral bones. Even though ELD treatment suppressed bone remodeling, it does not seem 321 
to increase the accumulation of bone microdamage. This favorable effect on microdamage may be due to there 322 
being no increase in the formation of AGEs in bone by the treatment with ELD. 323 
Fibrillar type I collagen is the most abundant matrix protein in bone [3][22][29][30][34][44]. Stabilization 324 
of newly formed collagen fiber is initially achieved by the formation of covalent crosslinks between 325 
neighboring collagen molecules, and this covalent intermolecular crosslinking by post-translational 326 
modification is crucial for the stability of collagen fibrils. These collagen crosslinks can be divided into two 327 
types: crosslinks controlled by lysyl hydroxylase (LH) and lysyl oxidase (LOX) (enzymatic crosslinks) and 328 
AGE crosslinks (non-enzymatic crosslinks). Collagen crosslink formation is thought to affect the mechanical 329 
properties of bone at a material level. Impaired formation of enzymatic crosslinks and/or an increase in non-330 
enzymatic crosslinks in bone collagen may contribute to the impaired bone mechanical properties seen in 331 
aging, osteoporosis, and diabetes mellitus [3][17][19][20][22][23][28][29][30]. Active vitamin D, calcitriol, 332 
has been shown to strongly upregulate gene expression of lysyl hydroxylases (LH1 and LH2b) and lysyl 333 
oxidase (LOXL2) in osteoblasts in vitro [45]. Treatment with the active vitamin D3 analog alfacalcidol 334 
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stimulates LOX expression, and dose-dependently increases total enzymatic collagen crosslink content 335 
(DHLNL, HLNL, LNL, Pyr, Dpyr) in tibial cortical bones of OVX rats in vivo [46]. We also demonstrated in a 336 
fracture repair OVX rat model that alfacalcidol stimulated the formation of enzymatic crosslinks in callus 337 
collagen, resulting in an increase of bone strength [22]. In the current study, ELD treatment increased the total 338 
contents of enzymatic collagen crosslinks (DHLNL, HLNL, LNL, Pyr, Dpyr) in the lumbar vertebral bones of 339 
cynomolgus monkeys, regardless of their bone mineralization status. This observation suggests that, similar to 340 
calcitriol, ELD increases the production of both immature divalent and mature trivalent enzymatic crosslinks 341 
by directly stimulating LH or LOX gene expression in bones. Therefore, ELD may be able to improve collagen 342 
crosslinks in bones independently from bone turnover. We have reported that, in the OVX monkey model, 343 
elevated enzymatic crosslink formation after treatment with teriparatide is an independent factor contributing 344 
to increasing vertebral bone strength [16]. Therefore, the increase in the content of enzymatic crosslinks by 345 
ELD treatment in the OVX primate model (Fig. 3 and Table 3) may contribute to increased bone strength [6]. 346 
The accumulation of young, newly formed collagen matrix by minimodeling may account for the observation 347 
that accumulation of senescent types of crosslinking AGEs in bone after treatment with ELD is less than that in 348 
bone from the OVX-vehicle control group. 349 
Histological analysis of trabecular bone sections from ELD-treated cynomolgus monkeys showed bone 350 
minimodeling, which is characterized by focal bone apposition directly to quiescent surfaces without prior 351 
bone resorption, as reported previously in OVX rats [8]. At sites of minimodeling, the mineralization process 352 
seems intact (Fig. 4). We do not know how this focal bone formation starts. However, small-size bone 353 
formation may affect the bone microarchitecture, and may ultimately change the degree of mineralization of 354 
trabecular bone. 355 
One of the limitations in this study is the substantial differences exist in the biological parameters between 356 
the two OVX-control groups due to the biological variability of nonhuman primates. For each experiment, we 357 
selected animals from the colonies with the same criteria, and randomly assigned to either OVX-control group 358 
or ELD-treated group. Thus, it is suitable to compare the results from the OVX-control group with those from 359 
the ELD-treated group within the experiment. However, it may be difficult to discuss the dose-dependent 360 
effects of ELD from this study. We believe this variability does not confound the interpretation of the data. 361 
17 / 27 
Other limitations are the absence of sham-operated control groups and the relatively short period of treatment. 362 
Not all of the measurements were performed on the same bone: Bone mechanical properties, bone 363 
mineralization, and collagen crosslinks were evaluated in L3 vertebrae; bone microdamage and bone 364 
microarchitecture were measured in L4 vertebrae; and assessment of bone histology was conducted with L2 365 
vertebrae. Therefore, the improvement of bone mechanical properties seen in this study might not directly 366 
connect with the results from other analyses. Nevertheless, we can conclude that the increase in the degree of 367 
bone mineralization and the contents of enzymatic collagen crosslinks may partly contribute to the increased 368 
bone strength of the lumbar vertebral bone in OVX cynomolgus monkeys treated with ELD. We conclude that 369 
ELD provides positive effects on bone quality, complementing our earlier studies showing its positive effects 370 
on bone mass and strength. 371 
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Figures and Tables 496 
Table 1  Microdamage analysis of vertebral trabecular bone 497 
 
Crack number 
Crack length  
(µm) 
Crack density  
(/mm2) 
Crack surface density  
(µm/mm2) 
OVX-Veh1 10.6 ± 3.3 78.0 ± 3.6 1.21 ± 0.23 97.7 ± 21.0 
ELD 0.1 µg/kg 14.2 ± 4.1 77.7 ± 2.2 1.63 ± 0.51 132.5 ± 43.6 
p = 0.496 p = 0.940 p = 0.464 p = 0.478 
OVX-Veh2 20.8 ± 4.9 75.6 ± 3.2 2.06 ± 0.45 159.5 ± 36.2 
ELD 0.3 µg/kg 10.1 ± 2.0 80.5 ± 3.8 0.92 ± 0.18 77.3 ± 17.1 
 
p = 0.052 p = 0.353 p = 0.027 p = 0.049 
Data are represented as mean ± SEM. P-values less than 0.05 are considered statistically significant. 498 
  499 
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Table 2  Evaluation of trabecular connectivity in lumbar vertebrae  500 
Experiment 1 OVX-Veh1 ELD 0.1 µg/kg P-value 
Number of termini (/mm2) 2.55 ± 0.26 2.19 ± 0.19 0.253 
Number of nodes (/mm2) 1.68 ± 0.15 2.23 ± 0.15 0.020 
Terminus to terminus strut length (mm/mm2) 0.24 ± 0.02 0.13 ± 0.02 0.003 
Node to terminus strut length (mm/mm2) 0.78 ± 0.06 0.76 ± 0.04 0.771 
Node to node strut length (mm/mm2) 0.79 ± 0.10 1.12 ± 0.07 0.015 
Total strut length (mm/mm2) 2.00 ± 0.10 2.25 ± 0.09 0.088 
Anisotropy ratio 0.80 ± 0.02 0.81 ± 0.01 0.622 
  
   
Experiment 2 OVX-Veh2 ELD 0.3 µg /kg P-value 
Number of termini (/mm2) 2.82 ± 0.12 1.89 ± 0.2 0.002 
Number of nodes (/mm2) 1.97 ± 0.09 2.3 ± 0.13 0.079 
Terminus to terminus strut length (mm/mm2) 0.24 ± 0.02 0.12 ± 0.02 0.002 
Node to terminus strut length (mm/mm2) 0.84 ± 0.02 0.78 ± 0.07 0.388 
Node to node strut length (mm/mm2) 0.82 ± 0.08 1.11 ± 0.08 0.025 
Total strut length (mm/mm2) 2.09 ± 0.07 2.2 ± 0.08 0.364 
Anisotropy ratio 0.79 ± 0.02 0.81 ± 0.02 0.614 
Data are presented as mean ± SEM. P-values less than 0.05 are considered statistically significant. 501 
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Table 3  Comparison of enzymatic and non-enzymatic crosslink contents between the OVX-vehicle controls 503 
and the ELD-treated groups 504 
  Enzymatic crosslinks Non-enzymatic crosslinks 
  
Immature divalent forms 
(mol/mol of collagen) 
Mature trivalent forms 
































































































































0.165 ± 0.030* 140.5 ± 25.0# 
2.166 ± 
0.417* 
Data are represented as mean ±SD. 505 
*: p < 0.05 versus OVX-vehicle control. 506 
#: p < 0.05 between low-density fraction and high-density fraction in the same treatment groups 507 
   508 
 Abbreviations: dihydroxylysinonorleucine, DHLNL; hydroxylysinonorleucine, HLNL; lysinonorleucine, LNL; 509 
pyridinoline, Pyr; deoxypyridinoline, Dpyr;  pentosidine, Pen. 510 
 511 
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Figure 1.  Distribution profiles of bone mineralization as assessed by density fractionation.  513 
(A) Experiment 1: ELD 0.1 µg/kg group (grey bars) versus OVX-vehicle control (OVX-Veh1; white bars). 514 
(B) Experiment 2: ELD 0.3 µg/kg group (grey bars) versus OVX-vehicle control (OVX-Veh2; white bars).  515 
Data are presented as mean + SEM. Box-and-whisker plots show median, 25th and 75th quartiles, and 516 
complete data range of the logit numbers of Experiment 1(C) and Experiment 2 (D)  517 
. 518 
Figure 2.  Backscattered electron microscopic imaging of the sagittal plane of lumbar vertebrae (L4). 519 
(A) OVX-vehicle control (OVX-Veh1), (B) ELD 0.1 µg/kg group, (C) OVX-vehicle control (OVX-Veh2), 520 
(D) ELD 0.3 µg/kg group. 521 
 522 
Figure 3.  Collagen crosslinks in primate vertebral bone (L2). Bone samples were divided into low-density 523 
fraction (< 2.0 mg/mL) and high-density fraction (≥ 2.0 mg/mL).  524 
(A) Total content of enzymatic crosslinks: the sum of immature (DHLNL, HLNL, LNL) and mature (Pyr, 525 
Dpyr) crosslinks in bone from the OVX-vehicle control (OVX-Veh1) and ELD 0.1 µg/kg group, (B) Content 526 
of non-enzymatic crosslink (Pen) in bone from the OVX-vehicle control (OVX-Veh1) and ELD 0.1 µg/kg 527 
group, (C) Total content of enzymatic crosslinks: the sum of immature (DHLNL, HLNL, LNL) and mature 528 
(Pyr, Dpyr) crosslinks in bone from the OVX-vehicle control (OVX-Veh2) and ELD 0.3 µg/kg group, 529 
(D) Content of non-enzymatic crosslink (Pen) in bone from the OVX vehicle control (OVX-Veh2) and ELD 530 
0.3 µg/kg group. 531 




 quartiles, and complete data range. 532 
 533 
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Figure 4.   Representative histological images of bone minimodeling. Trabecular bone sections of lumbar 534 
vertebrae from monkeys treated with ELD 0.3 µg/kg were observed under a light microscope or fluorescence 535 
microscope.  536 
(A) Histological section with toluidine blue staining shows focal, convex bone (arrowheads)—indicative of 537 
minimodeling—forming on the smooth line of the underlying bone matrix (arrows). (B) Fluorescence 538 
microscopy image of an ELD-treated specimen. Note continuous, convex calcein labeling at the site of bone 539 
minimodeling (white arrow). 540 
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